<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789434</url>
  </required_header>
  <id_info>
    <org_study_id>NHL-PD1-1</org_study_id>
    <nct_id>NCT04789434</nct_id>
  </id_info>
  <brief_title>PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT</brief_title>
  <official_title>PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT: A Multicenter, Randomized Controlled Clinical Study on Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized controlled, prospective clinical trial. The objective is to&#xD;
      investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed&#xD;
      diffuse large B-cell lymphoma (DLBCL) patients after autologous hematopoietic stem cell&#xD;
      transplantation (ASCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized controlled, prospective clinical trial. The objective is to&#xD;
      investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed&#xD;
      diffuse large B-cell lymphoma (DLBCL) patients after autologous hematopoietic stem cell&#xD;
      transplantation (ASCT). 94 patients were randomly divided into two groups according to the&#xD;
      ratio of 1:1. The whole trial included screening period (day-28 to day-1), treatment period&#xD;
      (Tislelizumab, 200mg every 8 weeks, 12 times) and follow-up period (2 years after the&#xD;
      enrollment).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2-years after enrollment</time_frame>
    <description>Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria,or death from any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>2-years after enrollment</time_frame>
    <description>Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2-years after enrollment</time_frame>
    <description>Overall survival was defined as the time from the date of diagnosis to the date of death from any cause. Reported is the percentage of participants with event. of disease progression or relapse, using 2014 Lugano criteria,or death from any cause, whichever occurred first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Transplantation</condition>
  <condition>Chemotherapy</condition>
  <arm_group>
    <arm_group_label>PD-1 Inhibitor maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 Inhibitor Tislelizumab maintenance therapy dose：200mg frequency：1 time for 2 months duration：2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 Inhibitor Tislelizumab maintenance therapy</intervention_name>
    <description>PD-1 Inhibitor Tislelizumab maintenance therapy, 200mg, every 2 months, 12 times</description>
    <arm_group_label>PD-1 Inhibitor maintenance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female, aged 18-65;&#xD;
&#xD;
          2. newly-diagnosed high risk (aaipi 2-3 and aaipi 1 with large mass) DLBCL patients after&#xD;
             autologous stem cell transplantation;&#xD;
&#xD;
          3. Laboratory tests (blood tests, liver and renal function) meet the following&#xD;
             requirements:&#xD;
&#xD;
               1. Blood tests: white blood cell count ≥ 3.0 × 109 / L, absolute neutrophil count ≥&#xD;
                  1.5 × 109 / L, hemoglobin ≥ 90g / L, platelet ≥ 75 × 109 / L&#xD;
&#xD;
               2. Liver function: transaminase ≤ 2.5 × upper limit of normal value, bilirubin ≤ 1.5&#xD;
                  × upper limit of normal value;&#xD;
&#xD;
               3. Renal function: serum creatinine 44-133 mmol / L;&#xD;
&#xD;
          4. The score of ECOG was 0-2;&#xD;
&#xD;
          5. The subject or his legal representative must provide written informed consent before&#xD;
             the special examination or procedure of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. Severe complications or infection;&#xD;
&#xD;
          3. Lymphoma involving central nervous system;&#xD;
&#xD;
          4. Participate in other clinical trials at the same time;&#xD;
&#xD;
          5. According to the judgment of the researcher, the patients who are not suitable for&#xD;
             this study were selected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weili Zhao, doctor</last_name>
    <phone>+862164370045</phone>
    <email>zwl_trial@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengpeng Xu, doctor</last_name>
    <phone>+862164370045</phone>
    <email>pengpeng_xu@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

